Navigation Links
Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock

SUNNYVALE, Calif., March 7, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases, today announced that it has commenced an underwritten registered public offering of 2,200,000 shares of its common stock, representing approximately 3.1% of the shares of common stock currently outstanding. All of the shares are being sold by Pharmacyclics.

J.P. Morgan Securities LLC is acting as sole manager for the proposed offering. Pharmacyclics intends to grant the underwriter a 30-day option to purchase up to an additional 330,000 shares of common stock to cover over-allotments, if any. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the final size or terms of the offering.

Pharmacyclics intends to use the net proceeds from this offering to accelerate commercial readiness for Ibrutinib post Breakthrough Therapy Designation, to advance its clinical pipeline, including expanding clinical development of Ibrutinib in additional indications, to evaluate strategic opportunities to potentially add synergistic assets, and for general corporate purposes.   

The shares will be issued pursuant to an effective shelf registration statement on Form S-3 filed today with the Securities and Exchange Commission. Pharmacyclics has filed with the Securities and Exchange Commission a preliminary prospectus supplement with respect to the offering.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Pharmacyclics, nor shall there be any offer or sale of securities in any state or jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from J.P. Morgan Securities LLC via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York, 11717 or by calling toll-free (866) 803-9204.

About Pharmacyclics

Pharmacyclics, Inc., headquartered in Sunnyvale, California, is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Its corporate mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious medical healthcare needs; and to identify promising product candidates based on scientific and administrational development expertise, develop our product candidates in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several research molecules in lead optimization. The Company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs toward viable commercialization.

Pharmacyclics, Inc. Contacts:

Joshua T. Brumm
Executive Vice President, Finance
Phone: 408-215-3311

Ramses Erdtmann
Senior Vice President of Investor Relations
Phone: 408-215-3325



SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
(Date:11/30/2015)... , November 30, 2015 --> ... report "Dental Lasers Market by Product (Soft Tissue, All Tissue, ... User (Hospitals, Clinics), and Geography - Global Forecast to 2020", ... by 2020, at a CAGR of 5.2% during the forecast ... market data Tables and 62 Figures spread through 167 P ...
(Date:11/30/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ), a clinical-stage ... delivery systems, announced today it has signed definitive licensing ... of Technologies Co., Ltd. ("HTIT") for exclusive rights to ... China , Hong Kong ... signed at the Israel Knesset (Parliament). ...
(Date:11/30/2015)... , Nov. 30, 2015   Nuance Communications, ... The National Decision Support Company (NDSC) today jointly ... and collaboration capabilities that utilize the American College of ... healthcare provider organizations to comply with current and ... --> --> By combining clinical decision ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... The world of hair ... and follicular unit extraction. These techniques and procedures have been in use for many ... hair loss. While Dr. Parsa Mohebi, M.D. has utilized many of these methods over ...
(Date:11/30/2015)... ... , ... The presidential race normally deals with political issues of national importance ... news story when Donald Trump makes disparaging remarks about Hillary Clinton’s hairstyle? It is ... wants to admit when it comes to how people are viewed by others. , ...
(Date:11/30/2015)... Los Angeles, CA (PRWEB) , ... November 30, 2015 , ... ... hunger cravings that drive people to overeat are not necessarily caused by real hunger, ... brain that the stomach needs food. He notes that, while many patients are aware ...
(Date:11/30/2015)... ... November 30, 2015 , ... RoamRight, a leading provider of ... Public Television’s Travel With Kids to promote family vacations around the world. ... they explore international destinations and educate families about the people and places of the ...
(Date:11/30/2015)... ... November 30, 2015 , ... At Grand Dental PC, ... convenient setting. , When you have dental problems, you need to turn to a ... effectively diagnose and treat your needs, a friendly dentist who counsels you on the ...
Breaking Medicine News(10 mins):